Title of Invention	NOVEL TRIAZOLE COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Abstract	The present invention relates to novel triazole compounds of formula (I), their pharmaceutically acceptable salts thereof, their pharmaceutical compositions containing them. where the symbols are defined in the description. The present invention also relates to a process for the preparation of the above said novel compounds.

Full Text

Field of the Invention The present invention relates to novel triazole compounds of formula (I), 4 _ and their pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds. Background of the Invention Since the discovery of penicillin, pharmaceutical companies have produced more than one hundred antibacterial agents to combat a wide variety of bacterial infections. In the past several years, there has been rapid emergence of bacterial resistance to several of these antibiotics. The multidrug resistance among these bacterial pathogens may also be due to mutation leading to more virulent clinical isolation, the most disturbing milestone has been the acquisition of resistance to vancomycin, an antibiotic generally regarded as the agent of last resort for serious Gram-positive infections. This growing multidrug resistance has recently rekindled interest in the search for new structural class of antibiotic that inhibit or kill these bacteria possibly by novel mechanisms. A problem of larger dimension is the increasing incidence of the more virulent, methicillin-resistant Staphylococcus aureus (MRSA) among clinical isolates found worldwide. As with vancomycin resistant organisms, many MRSA strains are resistant to most of the known antibiotics, but MRSA strains have remained sensitive to vancomycin. However, in view of the increasing reports of vancomycin resistant clinical isolates and growing problem of bacterial resistance, there is an urgent need for new molecular entities effective against the emerging and currently problematic Gram-positive organisms. Recently, several oxazolidinones have been discovered, which inhibit protein synthesis by binding to the 50S-ribosomal subunit which is close to the site to which chloramphenicol and lincomycin bind but their mode of action is mechanistically distinct from these two antibiotics. Various 1,2,3-triazoles, 1,2,4-triazoles and benzotriazoles have been reported to show various biological activities and have therefore found applications in medicinal chemistry. The literature survey shows the use of 1,2,3-triazoles, for the treatment of neuropathic pain and associated hyperalgesia, including trigeminal and herpectic neuralgia, diabetic neuropathic pain, migraine, causalgia and deafferentation syndromes such as brachial plexus avulsion, an anticoccidiostat, as antiproliferative agents, for antimetastatic activity in a model of ovarian cancer progression, for anti-inflammatory effect, controlling activity against noxious organisms, for the treatment of ischemia, anti-human immunodeficiency virus activity etc. Recently one PCX publication no. WO03/059894 showed the use of 1,2,3-triazole derivates as antiinfective agents. The novel triazole compounds of the present invention is useful for the treatment of various infections including local infections and systemic infections, caused by number of human and veterinary pathogens like Gram-positve, Gram-negative, multi resistant bacteria as well as anaerobic organisms and other Myco bacterial species. Some of the available triazole references are given below: (a) Chem. Pharm. Bull. 48(12), 1935-1946 (2000) discloses the triazoles of formula (ia) and (ib), which are reported as antifungal agents, (b) US 6054471 discloses fluorinated triazoles of the formula (ii), which are reported for the treatment of neuropathic pain and associated hyperalgesia, including trigeminal and herpectic neuralgia, diabetic neuropathic pain, migraine, causalgia and deafferentation syndromes such as brachial plexus avulsion, (c) J. Med. Chem., 2843, 1991 discloses compound of formula (iii), which is an anticoccidiostat and also been found to have antiproliferative activity in several disease models and to posses antimetastatic activity in a model of ovarian cancer progression, (d) J. Heterocycl. Chem., 609, 1989 discloses compound of formula (iv), which is reported for anti-inflammatory effects, (e) EPO publication no 0304221 A2 discloses compounds of formula (v), which are reported as antiproliferative reagents. (f) PCX publication no. WO03/059894 (by Dr. Reddy's Laboratories Ltd.) discloses 1,2,3-triazoles as antibacterial agents. Summary of the Invention With an objective to develop novel compounds effective against a number of human and veterinary pathogens sensitive as well as resistant to various antiinfectives, including Gram-positive, Gram-negative, aerobic and anerobic bacteria. The pathogens such as MRSA, Streptococci including Str pneumoniae, Str. pyogenes, Enterococci as well as anaerobic organisms such as Bacteroides spp., Clostridia spp. species and Acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. fastidious Gram negative organisms, H. influenzae, M. catarrhalis and several other bacterial species resistant to fluoroquinolone, Macrolide, Vancomycin, Aminoglycosides, Streptogramin, Lincosamides and β-Lactam, we focussed our research to develop new compounds effective against the above mentioned organisms, as well as expanded spectra of activity to include community acquired pneumonia (CAP). Efforts in this direction have led to the preparation of compounds having general formula (I) as defined above. The present invention provides novel 1,2,3-triazole derivatives of the general formula (I) as defined above, and their pharmaceutically acceptable salts thereof, their pharmaceutical compositions containing them. An aspect of the present invention is to provide pharmaceutical compositions containing compounds of the general formula (I), in combination with suitable carriers, solvents, diluents and other media normally employed in preparing such compositions. Detailed description of the Invention The present invention relates to compounds having the general formula (I), and their pharmaceutically acceptable salts thereof, their pharmaceutical compositions thereof; where R1 represents halogen, azido, thioalcohol, isothiocyanate, hydroxy, isoindole-1,3- dione, optionally substituted (C1-C10)alkylsulfonyloxy, arylsulfonyloxy, (C1-C10)acyloxy group, -SO2-(C1-C10)alkyl, -SO2-aryl; NHR4 where R4 represents (a) hydrogen, where Q represents oxygen or sulfur, R5 represents (i) hydrogen, Optionally substituted groups selected from, (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (ix) aryloxy, (x) heteroaryl, (xi) heterocyclyl, (xii) heteroaryloxy, (xiii) -NH-R6 where R6 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, and Q1represents oxygen or sulfur; (xiv) -N-[alkyl]2, (xv) -N(R'R"), wherein R' and R" together form a optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; (xvi) -SR , wherein R is as defined above; wherein R represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, aryl or aralkyl; R^ represents optionally substituted groups selected from (i) alkyl, (ii) cycloalkyl, (iii) alkoxy, (iv) cycloalkoxy. (v) alkenyl, (vi) alkenyloxy, (vii) aryl, (viii) aryloxy, (ix) heteroaryl, (x) heteroaryloxy, (xi) -NH-R10where R10epresents hydrogen or optionally substituted -alkyl, (xii) -N-[alkyl]2; R , and R at each occurrence are the same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) OR1where R are presents hydrogen or optionally substituted alkyl group; Y1represents =O Y2 and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =0, (ix) =S, Optionally substituted groups selected from (x) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR ) where R represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3; and n represents 1-3. The invention also provides triazole derivatives that have the general structure (Ila) where Q represents oxygen or sulfur, R5 represents (i) hydrogen, Optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (ix) aryloxy, (ix) heteroaryl, (x) heterocyclyl, (xi) heteroaryloxy, (xii) -NH-R6, where R6 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, alkenyl, alkenyloxy, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaryloxy, and Q1 represents oxygen or sulfur; (xiii) -N-[alkyl]2, (xiv) -N(R'R")» wherein R' and R" together form a optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; (xv) -SR , wherein R is as defined above; R^, and R^ at each occurrence are the same or different and are (xi) hydrogen, (xii) halogen, (xiii) cyano, (xiv) nitro, (xv) amino Optionally substituted groups selected from (xvi) alkyl, (xvii) haloalkyl, (xviii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y2, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (x) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl. The invention also provides triazole derivatives that have the general structure (lib) and their pharmaceutically acceptable salts thereof, where R^ represents (i) hydrogen, optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (x) heteroaryl, (xii) -NH-6^, where R6 represents hydrogen, optionally substituted groups selected from alkyl or cycloalkyl (xiii) -N-[alkyl]2, (xiv) -N(R'R"), wherein R' and R" together form a optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; Y% and Y^ may be present on any of the carbon atoms of the hetercyclic ring and are independently represent hydrogen, cyano, amino, formyl, =0, =S, alkyl or hydroxyalkyl; R , and R at each occurrence are the same or different and are selected from hydrogen, halogen, cyano, hydroxyl, alkyl, haloalkyl; m represents 0-3, n represents 1-3. In one embodiment of compounds of formula (lib), R represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, alkenyloxy, -NH-R6 where in R6 represents hydrogen, alkyl or cycloalkyl, -N-[alkyl]2. In another embodiment of compounds of formula (lib), R5 represents N(R'R") wherein R' and R" together form a optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N. The invention also provides triazole derivatives that have the general structure (lie) and their pharmaceutically acceptable salts thereof, where R5 represents (i) hydrogen, Optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (xix) heteroaryl, (xx) heterocyclyl, (xiii) -NH-R , where R represents hydrogen, optionally substituted groups selected from alkyl or cycloalkyl (xiv) -N-[alkyl]2, (xv) -N(R'R"), wherein R' and R" together form a optionally substituted substituted a 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; Y2, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent hydrogen, cyano, amino, formyl, =0, =S, alkyl or hydroxyalkyl; R2 and R2 at each occurrence are the same or different and are selected from hydrogen, halogen, cyano, hydroxyl, alkyl, haloalkyl; m represents 0-3, n represents 1-3. In one embodiment of compounds of formula (lIIc), R5 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, alkenyloxy, -NH-R6 where in R6 represents hydrogen, alkyl or cycloalkyl, -N-[alkyl]2, -N(R'R") wherein R' and R" together form a optionally substituted a 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N. The groups defined above are described as follows: 'Halogen' is fluorine, chlorine, bromine, or iodine; 'Alkyl' group is optionally substituted linear or branched (C1-C10)alkyl group. Exemplary alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl and the like. 'Haloalkyl' group is optionally substituted linear or branched halo(C1-C10)alkyl group. Exemplary alkyl groups include halomethyl, haloethyl, halopropyl, halobutyl, halopentyl, halohexyl, haloheptyl, halooctyl, haloiso-propyl, haloiso-butyl and the like. 'Hydroxyalkyl' group is optionally substituted linear or branched hydroxy(Ci-CI o)alky 1 group. Exemplary alkyl groups include hydroxymethyl, hydroxy ethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, hydroxyheptyl, hydroxyoctyl and the like. 'Cycloalkyl' group is optionally substituted (C3-C8)cycloalkyl group. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. 'Alkoxy' is optionally substituted (C1-C10)alkyl-O-, wherein the (C1-C10)alkyl group is as defined above. Exemplary alkyl groups include methoxy, ethoxy, propoxy, butoxy, iso-propoxy and the like. 'Cycloalkoxy' is optionally substituted (C3-C8)cycloalkoxy group. Exemplary cycloalkoxy groups include cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy and the like. 'Alkenyl' is optionally substituted (C2-Cio)alkenyl group. Exemplary alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like. 'Cycloalkenyl' is optionally substituted (C3-C10)cycloalkenyl group. Exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and the like. 'Alkoxyalkyl' is a (C1-C10)alkoxy(C1-C10)alkyl group, where alkoxy and alkyl groups are as defined above. Exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, methoxyisopropyl, ethoxyisobutyl and the like. 'Alkoxycarbonyl' is optionally substituted (C1-C10)alkoxycarbonyl, wherein (c1-C10)alkoxy is as defined above. Exemplary alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl and the like. 'Carboxyalkyl' is optionally substituted carboxy(C1-C10)alkyl, where (C1-C10)alkyl group is as defined above. Exemplary carboxyalkyl groups include carboxymethyl, carboxyethyl and the like. 'Alkylsulfonyl' is optionally substituted (C1-C10)alkylsulfonyl, where (C1-C10)alkyl group is as defined above. Exemplary alkylsulfonyl groups include methylsulfonyl, ethylsulfonyl and the like 'Alkylsulfonyloxy' is optionally substituted (C1-C10)alkylsulfonyloxy, where (C1-Cio)alkyl group is as defined above. Exemplary alkylsulfonyloxy groups include methylsulfonyloxy, ethylsulfonyloxy and the like. ' Aryl' is optionally substituted monocylic or multicyclic ring system of about 6 to 14 carbon atoms. Exemplary groups include phenyl, naphthyl and the like. 'Arylsulfonyloxy' is optionally substituted arylsulfonyloxy, where aryl group is as defined above. Exemplary arylsulfonyloxy groups include phenylsulfonyloxy, naphthylsulfonyloxy and the like. 'Alkylcarbonylaminoalkyl' is optionally substituted (Ci- Cio)alkylcarbonylamino(C1-C10)alkyl, where (C1-C10)alkyl group is as defined above. Exemplary alkylcarbonylaminoalkyl groups include methylcarbonylaminomethyl, methylcarbonylaminoethyl and the like. 'Arylcarbonylaminoalkyl' is optionally substituted arylcarbonylamino(Ci-Cio)alkyl, where aryl and (C1-C10)alkyl group are as defined above. Exemplary arylcarbonylaminoalkyl include phenylcarbonylaminomethyl, phenylcarbonylaminoethyl and the like. 'Alkylcarbonyloxyalkyl' is optionally substituted (C1-C10)alkylcarbonylamino(C]-Cio)alkyl, where (C1-C10)alkyl group is as defined above. Exemplary alkylcarbonyloxyalkyl groups include methylcarbonyloxymethyl, ethylcarbonyloxymethyl and the like. 'Aminoalkyl' is amino(C1-C10)alkyl, where (C1-C10)alkyl is as defined above. Exemplary aminoalkyl groups include aminomethyl, aminoethyl and the like. 'Monoalkylamino' is 'Mono(C1-C10)alkylamino' where (C1-C10)alkyl is as defined above. Exemplary monoalkylamino groups include methylamino, ethylamino, propylamino, isopropylamino and the like. 'Dialkylamino' is 'Di(C1-C10)alkylamino' where (C1-C10)alkyl is as defined above. Exemplary dialkylamino groups include dimethylamino, diethylamino and the like. 'Arylamino' where aryl group is as defined above. Exemplary arylamino groups include phenylamino, naphthylamino and the like. 'Alkenyloxy' is optionally substituted (C3-Cio)alkenyl-0-, where the (C2-C6)alkenyl group is as defined above. Exemplary alkenyl groups include ethenyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy and the like. 'Acyloxy' is (C1-C10)acyl-O-, where acyl group is defined as H-CO- or (Ci-Cio)alkyl-CO-, where (C1-C10)alkyl group is as defined above. Exemplary acyl groups include acetyl, propionyl, and the like. Exemplary acyloxy groups include acetyloxy, propionyloxy, and the like. 'Aryloxy' is optionally substituted aryl-0- group, where the aryl group is as defined above. Exemplary aryloxy groups include phenoxy, naphthyloxy and the like. 'Aralkyl' is optionally substituted aryl-(C1-C10)alkyl group, wherein aryl and (Cr Cio)alkyl groups are as defined above. Exemplary aralkyl groups include benzyl, 2-phenylethyl and the like. 'Aralkoxy' is optionally substituted aralkyl-0- group, wherein the aralkyl group as defined above. Exemplary aralkoxy groups include bezyloxy, 2-phenethyloxy and the like. 'HeterocyclyP is optionally substituted non-aromatic saturated monocyclic or multicyclic ring system of about 5 to about 10 carbon atoms, having at least one hetero atom selected fi:om O, S or N. Exemplary heterocyclyl groups include aziridinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl, 1,4-dioxanyl and the like. 'Heteroaryl' is optionally subtituted aromatic monocyclic or multicyclic ring system of about 5 to about 10 carbon atoms, having at least one heteroatom selected from O, S or N. Exemplary heteroaryl groups include as pyrazinyl, isothiazolyl, oxazolyl, pyrazolyl, pyrrolyl, pyridazinyl, thienopyrimidyl, furyl, indolyl, isoindolyl, 1,3-benzodioxole, 1,3-benzoxathiole, quinazolinyl, pyridyl, thiophenyl and the like. 'Heteroaralkyl' is optionally substituted heteroaryl-(C1-C10)alkyl group, wherein the heteroaryl and (C1-C10)alkyl groups are as defined above. Exemplary heteroaralkyl groups include thienylmethyl, pyridylmethyl, imidazolylmethyl and the like. 'Heteroaryloxy' is optionally substituted heteroaryl-0-, wherein the heteroaryl group is as defined above. Exemplary heteroaryloxy groups include pyrazinyloxy, isothiazolyloxy, oxazolyloxy, pyrazolyloxy, phthalazinyloxy, indolyloxy, quinazolinyloxy, pyridyloxy, thienyloxy and the like. The optionally substituted heterocyclic rings fomed by R' and R" may be selected from pyrrolidino group, a piperidino group, a piperazino group, a morpholino group or a thiomorpholino group and the like. The substituents on the above defined groups may be selected from hydrogen, halogen, nitro, amino, mono or di substituted amino, hydroxy, alkoxy, carboxy, cyano, oxo(0=), thio(S=), alkyl, cycloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, benzyloxy, acyl, acyloxy, aroyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryl, heterocyclyl, aralkyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, alkylthio, arylthio, heteroarylthio or aralkylthio, Heterocyclyl sulfonyl, which may further optionally substituted by halogen, hydroxyl, nitro, amino, alkyloxy, hetero cyclyl may be selected from morpholinyl, thiomorphoine, piperzine and like. The optional substitution of the above defined groups may take place on one or two or three possible carbon atoms of the above defined groups. Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; salts of organic bases such as N,N'-diacetylethylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2- dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N' - diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine, and the like; chiral bases like phenylalkylamine, substitutedglycinol and the like, salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids such as D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl such as methyl, ethyl, propyl and the like; alkenyl such as ethenyl, propenyl, butenyl and the like; alkynyl such as ethynyl, propynyl and the like; ammonium or substituted ammonium salts and aluminum salts. Salts may include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, halides, acetates, tartrates, maleates, citrates, succinates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like. Particularly useful compounds according to this invention include, but not limited The present invention also relates to a process for the preparation of the compound of formula (I) where R1 represents NHR4 wherein R4 represents hydrogen atom and all other symbols are as defined earlier, the process is as shown in the Scheme-I: Scheme-I The compound of formula (Ic) may be prepared by reacting a compound of formula (la), wherein X represents halogen atom, with a compound of formula (lb) by using a base such as KOH, NaOH, K2CO3, Na2CO3, NaH, KH, triethylamine, diisopropylethyl amine and the like. The reaction may be carried out using a solvent such as DMSO, DMF, THF, acetonitrile, chloroform, nitrobenzene and the like or mixtures thereof The reaction may be carried out in inert atmosphere, which may be maintained using inert gases such as N2 or Ar. The reaction may be carried out at a temperature in the range of about 20 to 100°C, preferably in the range of about 20 to 80 °C. The reaction time may range from about 1 to 15 hours, preferably about 6 to 12 hours. The compound of formula (Ic) is converted to a compound of formula (Id). The reaction may be carried out in the presence of reducing agents such as NiCl2/NaBH4, lithium aluminium hydride (LAH), gaseous hydrogen and a catalyst such as Ru, Pd, Rh, Pt, Ni on solid beads such as charcoal, alumina, asbestos and the like, in presence of a solvent such as dioxane, acetic acid, ethyl acetate, THF, alcohol such as methanol, ethanol and the like or mixtures thereof. A pressure between atmospheric to 60 psi is used. The reaction is carried out at a temperature about 0 to 60 °C, preferably about 0 to 40 °C. The reaction period ranges from about 0.5 to 48 hours, preferably in the range of about 0.5 to 5 hours. The reduction may also be carried out by employing metal in mineral acids such Sn/HCl, Fe/HCl, Zn/HCl, Zn/CH3C02H and the like. The compound obtained is further treated with NaNOz in the presence of HCl or CH3COOH followed by NaNa. The temperature of the reaction is maintained in the range of about -40 °C to boiling temperature, preferably in the range of about 0 to 35 °C, The duration of the reaction may be in the range of about 0.5 to 15 hours, preferably about 0.5 to 5 hours. The compound of formula (Id) is converted to a compound of formula (le) by using a reagent (BOC)2O. The base used in the reaction is selected from DMAP, pyridine, ethylamine, NaH, KH, diisopropyl ethylamine or Et3N and the like. The temperature and duration of the reaction about 0 to 100 °C, preferably about 0 to 30 °C, and about 1 to 24 hours, preferably about 1 to 12 hours, respectively. The compound of formula (le) is converted to a compound of formula (If), where R' represents hydroxy group and Z represent NR*' wherein R^ represents hydrogen atom, by treating with propargyl alcohol in the presence of a reagent such as Cul, CUSO4 and the like. The reaction may be carried out in the presence of amine selected from diisopropylethylamine, Et3N, 2,6-lutidine and the like. The solvent used in the reaction may be selected from benzene, toluene, xylene, acetonitrile, THF, dioxane, DMF and the like. The temperature of the reaction may be maintained in the range of about 10 to 200 °C, preferably 20 °C to the boiling temperature of the solvent. The duration of the reaction may be in the range of about 2 to 48 hours, preferably about 12 to 24 hours. The compound of formula (If), where R1 represents hydroxy group, is converted to a compound of formula (If), where R^ represents azido group and Z represent NR*^ wherein R*' represents hydrogen atom, is carried out by treating with alkylsulfonylchloride or arylsulfonylchloride such as methanesulfonyl chloride, p-toluenesulfonyl chloride and the like. The reaction is carried out in the presence of chloroform, dichloromethane, THF, dioxane and the like. The base used in the reaction is selected from EtaN, diisopropyl ethylamine, NaaCO3, K2CO3 and the like. The temperature of the reaction is maintained in the range of about 0 to 50 °C, preferably in the range of about 0 to 35 °C. The duration of the reaction is in the range of about 1 to 12 hours, preferably in the range of about 1 to 4 hours. The resultant compound is converted to a compound of formula (I) wherein R represents azido group, by treating with NaN3. The solvent used in the reaction is selected from dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, nitromethane and the like. The tempearature of the reaction may be maintained in the range of about 20 to 120 °C, preferably about 20 to 80 °C. The duration of the reaction may be in the range of about 1 to 12 hours, preferably about 2 to 5 hours. The compound of formula (If), where R^ represents azido group is converted to a compound of formula (I), where R represents azido group is carried out in the presence of trifluroaceticacid (TFA), HCl, PTSA and the other related reagents. The solvent used in the reaction is selected from dichloromethane, chloroform and the like. The temperature and duration of the reaction is selected from about 0 to 100 °C, preferably about 20 to 60 °C. The duration of the reaction is maintained in the range of about 2 to 24 hours, preferably about 2 to 12 hours. The compound of formula (I), where R1 represents azido group is converted to a compound of formula (I) where R1 represents NHR4 wherein R4 represents hydrogen atom, by using triphenyl phosphine, in the presence of a solvent such as THF, DMF, toluene and the like, along with water. The above conversion could also be accomplished by using hydrogenation conditions used in the conversion of compound of formula (Ic) to (Id). The reaction may be carried out at a temperature in the range of about 25 to 40 ^C, preferably 20 to 35 °C. The duration of the reaction may be in the range from about 3 to 24 hours, preferably about 4 to 12 hours. The present invention also provides a process for the preparation of the compound of formula (I) where R1 represents NHR4 wherein R4 represents various groups as defined earlier; the process is as shown in the Scheme-II: C10)alkoxycarbonyl, (C1-C10)alkylthiocarbonyl or (C1-C10)arylthiocarbonyl, by treating with appropriate acid halide such as acetyl chloride, propionyl chloride and the like; alkylchloroformate hke methylchloroformate, ethylchloroformate and the like; aralkylchloroformate like benzylchloroformate and the like; or anhydride of the corresponding acid such as acetic anhydride. The reaction is carried out in the presence of a solvent such as CH2CI2, CHCI3, toluene, THF and the like or mixtures thereof The reaction may also be carried out in the presence of a base like EtaN, diisopropyl ethylamine, pyridine, K2CO3, NaH, t-BuOK and the like. The temperature of the reaction is maintained in the range of about -20 to 60 oC, preferably in the range of about 0 to 35 °C. The duration of the reaction is in the range of about 1 to 12 hours, preferably about 1 to 4 hours. Process (h): The compound of formula (I), where R' represents NHR4, wherein R4 represents hydrogen atom may be converted to a compound of formula (I) where R1 represents isothiocyanate group, by using thiophosgene or a combination of carbon disulfide and methylchloroformate in the presence of a base such as Et3N, K2CO3, NaOH and the like. The reaction is carried out in the presence of a solvent such as CH2CI2, CH3CN, CHCI3, DMF, THF and the like. The reaction is carried at a temperature in the range of 0 to 60°C, preferably at 0°C. The reaction is carried out in an inert atmosphere using argon or any other inert gas. The duration of the reaction is in the range of 1 to 24 hours, preferably 2 to 10 hours. The conversion of compound of formula (I) where R* represents isothiocyanate group, to a1 compound of formula (I), where R1 represents NHR4, wherein R4 represents optionally substituted -C(=S)-OR4b, wherein R4b is as defined above, is carried out by using respective alcohol such as methanol, ethanol, propanol, cyclohexanol and the like, in the absence or presence of a base such as NaH, KH and the like. The reaction is carried out in the absence or presence of a solvent such as THF, toluene, DMF and the like. The reaction is carried out at a temperature in the range of about 20 to 130 °C, preferably at reflux temperature of the solvent used. The duration of the reaction is in the range of about 6 to 24 hour. Process (c): The compound of fomula (I), where R1 represents NHR4, wherein R4 represents optionally substituted -C(=S)-SR'*^ wherein R"**" is as defined above, is prepared from compound of formula (I), where R1 represents NHR4, wherein R4 represents hydrogen atom, by using CS2 in the presence of a base such as Et3N, diisopropyl ethylamine, K2CO3, NaH, t-BuOK and the like. The reaction is carried out in the presence of alkyl halide such as methyhodide, ethylbromide, propylbromide and the like. The solvent used in the reaction is benzene, THF, diethylether, acetonitrile and the like, or mixtures thereof The reaction is carried out at a temperature in the range of about 20 to 60 °C, preferably at 20 to 35 °C. The duration of the reaction is in the range of about 6 to 24 hours. Process (d): The compound of fomula (I), where R1 represents NHR4, wherein R4 represents optionally substituted -C(=S)-NH-R'4d wherein R4d is as defined above, may be prepared from compound of formula (I), where R' represents NHR4, wherein R4 represents hydrogen atom by using benzoylisothiocyanate. The solvent used in the reaction is selected from acetone, ethanol, methanol, isopropanol, THF, diethylether, acetonitrile and the like. The temperature of the reaction is maintained in the range of about 0 to 80 °C, preferably in the range of about 20 to 60 °C. The duration of the reaction is in the range of about 1 to 20 hours, preferably in the range of about 1 to 10 hours. Process (e): The compound of fomula (I), where R1 represents NH4, wherein R4 represents optionally substituted -C(=0)-heteroaryl, is prepared from compound of formula (I), where R' represents NHR4, wherein R'^ represents hydrogen atom by treating with corresponding heteroaroyl acid chloride and base such such as pyridine, triethylamine or diisopropylamine. The reaction may also be carried out by using corresponding heteroaryl acid and dicyclohexylcarbodiimide (DCC) in the presence of dimethylaminopyridine (DMA?). The solvent used in the reaction is selected from acetonitrile, THF, Et20 and the like. The temperature of the reaction is maintained in the range of about -5 to 100 °C, preferably in the range of about 0 to 80°C. The duration of the reaction is in the range of about 1 to 15 hours, preferably in the range of about 2 to 12 hours. Process (f): The compound of formula (I) where R^ represents NHR"* where R"* represents optionally substituted group selected from -C(=NH)-NH2, -C(=NH)-NH(C1-C10)alkyl, -C(=NH)-[C1-C10)alkyl]2, is prepared by reacting the compound of formula (I), where R' represents NHR"^ where R"* represents hydrogen atom, with di-tert-bntoxy carbonyl thiourea in two steps. In the first step, the reaction is carried out in the presence of solvents such as DMF, acetone, THF, dichloromethane and the like. The base used in the reaction is selected from triethylamine, diisopropylethylamine, pyridine and the like. The temperature of the reaction is in the range of 0 to 120oC, preferably in the range of about 0 to 90°C. The duration of the reaction is in the range of about 0.2 to 15 hours, preferably in the range of about 0.5 to 10 hours. In the second step, the compound obtained in the first step is reacted with trifluoroacetic acid in the presence of a solvent such as dichloromethane, chloroform, THF and the like. The temperature of the reaction is in the range of about 0 to 110 °C, preferably in the range of about 0 to 90 'C. The duration of the reaction is in the range of about 0.5 to 60 hours, preferably in the range of about 0.5 to 54 hours. Process (gV The conversion of compound of formula (I), where R1 represents NHR4 where R'4 represents hydrogen atom, to a compound of formula (I), where R' represents NHR4, wherein R4 represents optionally substituted group selected from -S(0)2-(C1-C10)alkyl or -S(0)2-aryl group, may be carried out by treating with alkylsulfonylchloride or arylsulfonylchloride such as methanesulfonyl chloride, p-toluenesulfonyl chloride and the like. The solvent used may be selected from dichloromethane, tetrahydrofiiran, acetonitrile, dimethylformamide, dimethylsulfoxide and the like. The temperature of the reaction may be in the range of about 0 to 50 °C, for duration of about 1 to 6 hours. The present invention also provides an alternate process for the preparation of the compound of formula (I) where all symbols are as defined earlier, which is shown in the following Scheme-Ill The compound of formula (Ic) may be prepared by reacting a compound of formula (la) with a compound of formula (lb) by using a base such as potasiumhysdroxide (KOH), sodiumhydroxide (NaOH), potassiumcarbonate (K2CO3), sodiumcarbonate (NaaCOa), sodiumhydride (NaH), potassiumhydride (KH), triethylamine, diisopropylethyl amine and the like. The reaction may be carried out using a solvent such as dimethylsulfoxide (DMSO), dimethylformamide (DMF), tetrahydrofuran (THF), acetonitrile, chloroform, nitrobenzene and the like or mixtures thereof. The reaction may be carried out in inert atmosphere, which may be maintained using inert gases such as N2 or Ar. The reaction may be carried out at a temperature in the range of about 20 to 100 °C, preferably at a temperature in the range of about 20 to 80 °C. The reaction time may range from about 1 to 15 hours, preferably from about 6 to 12 hours. The reduction of a compound of formula (Ic) to produce a compound of formula (Id) may be carried out in the presence of reducing agents such as NiCl2/NaBH4, lithium aluminium hydride (LAH), gaseous hydrogen and a catalyst such as Ru, Pd, Rh, Pt, Ni on solid beads such as charcoal, alumina, asbestos and the like. The reduction may be carried out in the presence of a solvent such as dioxane, acetic acid, ethyl acetate, THF, alcohol such as methanol, ethanol and the like or mixtures thereof. A pressure between atmospheric pressure to 60 psi may be used. The reaction may be carried out at a temperature from about 0 to 60 ^C, preferably about 0 to 45 **C. The reaction time ranges from about 0.5 to 48 hours, preferably in the range of about 0.5 to 5 hours. The reduction may also be carried out by employing metal in mineral acids such Sn/HCl, Fe/HCl, Zn/HCl, Zn/CHsCOjH and the like, or Zn/NH4C1.. The compound of formula (Id) may be converted to a compound of formula (le) by using (sodium nitrite (NaNO2) in the presence of hydrochloride (HCl) or acetic acid (CH3COOH) followed by sodiumazide (NaNs). The temperature of the reaction may be maintained in the range of about -40 °C to boiling temperature of the solvent used, preferably in the range of 0 oC to boiling temperature. The duration of the reaction may be in the range of about 0.5 to 15 hours, preferably in the range of about 0.5 to 5 hours. The conversion can also be carried out by (C1 -C6)alkylnitrites such as isoamylnitrite,. t-butylnitrite and the like, in the presence of inorganic azides such as NaNa and the like. The solvent used in the reaction may be selected from acetonitrile, CHCI3, THF, DMF, DMSO, (Ci-C8)alcohols such as methanol, ethanol, propanol, iso-propanol, t-butylalcohol and the like. The temperature of the reaction may be in the range of about 0 °C to boiling temperature of the solvent used. The duration of the reaction is maintained in the range of about 15 minutes to 18 hours, preferably about 0.5 to 10 hours. The compound of formula (le) may be converted to a compound of formula (le') by treating with hydroxy lamine hydrochloride. The solvent used in the reaction is selected from chloroform (CHCI3), THF, acetonitrile, (Ci-C8)alcohol such as methanol, ethanol, propanol, iso-propanol, t-butylalcohol and the like. The reaction may be carried out in the presence of a base selected from triethylamine, pyridine, 4-dimethylaminopyridine (DMAP), sodium methoxide, sodium ehthoxide and the like. The temperature and duration of the reaction of the reaction may be maintained in the range of about 0 °C to boiling temperature of the solvent used and about 0.5 to 8 hours respectively. The compound of formula (le') is converted to a compound of formula (le") by Beckmann Rearragement reaction conditions. The compound of formulae formulae (d), (e), (e') and (e") is reacted with compound of formula (Ig), to obtain a compound of formula (I) by using Cu(I) halide in the presence or absence of a base such as DMAP, pyridine, triethylamine, diisopropylethylamine, 2,6-lutidine and the like. The solvent used in the reaction may be selected from DMF, DMSO, THF, ether, dioxane, acetonitrile and the like. The temperature and duration of the reaction may be maintained in the range of about 0 'C to boiling temperature of the solvent used and about 0.5 to 5 hours respectively. Yet another embodiment of the present invention provides a process for the preparation of compound of formula (I), where R^ represents NHR"^, wherein R** represents acetyl group and all other symbols are as defined earlier, from a compound of formula (I) where R* represents azido group, where all symbols are as defined earlier. The compound of formula (I), where R1 represents NHR4, wherein R4represents optionally substituted acetyl group may be prepared from compound of formula (I), where R1 represents azido group by using thiolacetic acid with or without using solvent such as THF, DMF, toluene and the like. The reaction may be carried out at a temperature in the range of about 25 to 40 °C, preferably 20 to 40 °C. The duration of the reaction may be in the range from about 3 to 24 hours, preferably about 4 to 12 hours. Still another embodiment of the present invention provides a process for the preparation of compound of formula (I), where R* represents NHR"^, where R"^ represents optionally substituted -C(=S)-R4e, wherein R'4e represents (C1-C10)alkyl, halo(Ci-C10)alkyl, (C3-C10)cycloalkyl, (C2-C]o)alkenyl, aralkyl, aryl, heteroaryl, from compound of formula (I), where R1 represents NHR4, where R4 represents optionally substituted - where all symbols are as defined earlier. The compound of formula (I), where R1 represents NHR4, wherein R4 represents optionally substituted -C(=S)-R4e, from compound of formula (I), where R1 represents NHR4, wherein R4 represents optionally substituted -C(=0)-R^, wherein R4e is as defined above, may be carried out by taking a solution of the amide and Lawesson's reagent (2,4-bis(methoxyphenyl)-l,3-dithia-2,4-diphosphetane-2,4-disulfide) in dry dioxane, toluene, THF, DMF, hexamethyldisiloxane (HDMA) and the like. The reaction may be carried out at a temperature in the range of about 20 to 130 °C, preferably about 55 to 90oC. The duration of the reaction may be in the range of about 3 to 24 hours, preferably about 3 to 10 hours. Another embodiment of the present invention provides a process for the preparation of compound of formula (I), where R1 represents NHR4, where R4 represents optionally substituted groups selected from -C(=S)-NH2, -C(=S)-NH-(CrC10)alkyl, -C(=S)-N-((C1-C10)alkyl)2, -C(=S)-NH-(C3-C10)cycloalkyl, -C(=S)-NH-(C1-C10)alkoxy, -C(=S)-NH-(C3-C10)cycloalkoxy, -C(=S)-NH-aryl, -C(=S)-NH-heteroaryl, -C(=S)-NH-(G2-C10)alkenyl, -C(=S)-NH-aralkyl, -C(-S)-NH-heteroaralkyl or -C(=S)-N(R'R"), wherein R' and R" groups together form a optionally substituted 5 or 6 membered cyclic structures containing nitrogen and optionally one or two additional hetero atoms selected from oxygen, nitrogen or sulfur; from a compound of formula (I) where R' represents isothiocyanate group, 4 n where all symbols are as defined earlier. The compound of formula (I), where R1 represents NHR4, wherein R4 represents optionally substituted -C(=S)-NH2, may be prepared by passing ammonia gas into a solution of compound of formula (I) where R1 represents isothiocyanate group, in the presence of a solvent such as THF, toluene, and the like. The reaction may be carried out at a temperature in the range of about -10 to 35 °C, preferably about -10 to 20 °C. The duration of the reaction may be in the range from about 20 minutes to 4 hours, preferably about 30 minutes. The compound of formula (I), where R' represents NHR4, wherein R4 represents optionally substituted groups selected from , -C(=S)-NH-(C1-C1O)alkyl, -C(=S)-N-((C1-C1O)alkyl)2, -C(=S)-NH-(C3-C1O)cycloalkyl, -C(=S)-NH-(C1-C1O)alkoxy, -C(=S)-NH-(C3-C1O)cycloalkoxy, -C(=S)-NH-aryl, -C(=S)-NH-heteroaryl, -C(=S)-NH-(C2-C1O)alkenyl, -C(=S)-NH-aralkyl, -C(=S)-NH-heteroaralkyl or -C(=S)-N(R'R"), wherein R' and R" groups together form a optionally substituted 5 or 6 membered cyclic structures containing nitrogen and optionally one or two additional hetero atoms selected from oxygen, nitrogen or sulfur, may be carried out by treating a compound of formula (I) where R1 represents isothiocyanate group with appropriate amine such as methylamine, ethylamine, diethylamine, benzylamine, aniline, proline, morpholine, thiomorpholine, pyridylmethylamine and the like, in the presence of a solvent such as THF, DMF, toluene, and the like. The reaction may be carried out at a temperature in the range of about 20 to 140 °C, preferably about 20 to 100 °C. The duration of the reaction may be in the range of about 0.5 to 24 hours, preferably about 0.5 to 12 hours. Another embodiment of the present invention provides an alternative process for the preparation of compound of formula (I) where R' represents NHR"^ where R4represents optionally substituted group selected from -C(=NH)-NH2, by reacting a compound of formula (I), where R^ represents NHR"^ wherein R"^ represents optionally substituted group selected from -S(O)2(C1-C1O)alkyl or -S(O)2aryl group, with guanidine hydrochloride, where all other symbols are as defined earlier. The compound of formula (I) where R4 represents NHR4 where R4 represents optionally substituted group selected from -C(=NH)-NH2, may be prepared by reacting the compound of formula (I), where R1 represents NHR4 wherein R4 represents optionally substituted group selected from -S(O)2(C1-C1O)alkyl or -S(O)2aryl group, with guanidine hydrochloride. The solvent used in the reaction may be seleceted from t-butyl alcohol, DMF. The base used in the reaction may be selected from NaH, KH, sodium hexamethyldisilazide (Na-HMDS) and the like. The temperature of the reaction may be in the range of about 0 °C to boiling temperature of the solvent used. The duration of the reaction may be in the range of about 1 to 30 hours, preferably in the range of about 1 to 24 hours. piperidine, DMAP, l,8-diazabicyclo[5.4.0]undec-7-ene (DBU), lithium diisopropylamide (LDA), potassium bis-(trimethyl silyl)amide, butyllithium (BuLi), Na2CO3, K2CO3, NaOH, KOH, sodiummethoxide (NaOMe), sodiumethoxide (NaOEt), sodium isopropoxide (NaOiPr), potassium tertiary butoxide (t-BuOK), NaH, KH and the like. The solvents used in the reaction may be selected from THF, ether, dioxane, toluene, benzene, DMF, DMSO, methylcyanide and the like. The temperature of the reaction may be maintained in the range of about -20 to 150 °C, preferably in the range of about -10 to 100 °C. The duraion of the reaction may be in the range of about 0.2 to 64 hours, preferably in the range of about 1 to 48 hours. In still another embodiment of the present invention there is provided a process for the preparation of compound of formula (I), where Z represents NRb wherein Rb represents optionally substituted (Ci-C6)alkyl or aralkyl, Y1 represents =O group', Y2 and Y3 independently represent hydrogen atom; from a compound of formula (I) where Z where all other symbols are as defined earlier. The compound of formula (I), wherein Z represents NRb wherein Rb represents optionally substituted (Ci-C6)alkyl or aralkyl, Y1 represents '=0 group', Y2 and Y3 independently represent hydrogen atom, from a compound of formula (I) wherein Z represents NRb wherein Rb represents hydrogen, Y1 represents '=O' group, Y2 and Y2 independently represent hydrogen atom, may be carried out in the presence of a base such as triethylamine, di-isopropylamine, di-isopropylethylamine, pyridine, piperidine, DMAP, l,8-diazabicyclo[5.4.0]undec-7-ene (DBU), lithium diisopropylamide (LDA), potassium bis-(trimethyl silyl)amide, BuLi, Na2CO3, K2CO3, NaOH, KOH, NaOMe, NaOEt, NaOiPr, t-BuOK, NaH, KH and the like, followed by reacting with alkyl halide such as methyliodide, methoxymethylchloride, allylbromide, benzylbromide and the like. The solvent used in the reaction may be selected from DMF, DMSO, THF, dioxane, benzene, toluene and the like. The temperature of the reaction may be maintained in the range of about -5 to 150 °C, preferably in the range of about 0 °C to reflux temperature of the solvent used. The duraion of the reaction may be in the range of about 0.2 to 48 hours, preferably in the range of about 0.5 to 24 hours. Another embodiment of the present invention there is provided a process for the preparation of a compound of formula (I) where R^ represents halogen, from compound of formula (I) where R^ represents hydroxy group, where all other symbols are as defined above. The compound of formula (I) where R1 represents halogen is prepared from compound of formula (I) where R1 represents hydroxy group may be carried out by treating with tetrahalomethane group such as CBr4, CCI4 and the like, in the presence of triphnyl phosphine (PPhs), P(alkyl)3 and the like. The reaction may be carried out in the presence of a solvent such as dry dichloromethane, chloroform, tetrachloromethane, benzene, DMF, DMSO, THF and the like. The temperature of the reaction may be maintained in the range of about 0 to 60 oC, preferably about 20 to 40 oC. The duration of the reaction may be in the range of about 2 to 24 hours, preferably about 8 to 13 hours. Another embodiment of the present invention provides a process for the preparation of a compound of formula (I) where R^ represents NHR4, where R"^ represents -C(=S)-N(R'R"), where R' represents hydrogen, (Ci-C6)alkyl, (C2-C6)alkenyl, optionally substituted aralkyl, heteroaralkyl, hydroxy(Ci-C6)alkyl and R" represents hydrogen or alkyl or the two R' and R" groups together form a 5 or 6 membered cyclic structures containing one or two hetero atoms selected from oxygen, sulfur or nitrogen, from a compound of formula (I) where R1 represents isothiocynate group, where all other symbols are as defined earlier. The compounds of above formula (I) may be prepared by treating the compound of formula (I), where R* represents isothiocyanate group with heterocycles such as morpholine, piperidine, pyrrolidine and the like in the presence or absence of a solvent. The temperature of the reaction may be maintained in the range of about 0 °C to reflux temperature of the solvent used, preferably about 20 to 35 oC. The duration of the reaction is maintained in the range of about 1 to 24 hours, preferably about 1 to 12 hours. Another embodiment of the present invention provides a novel intermediate of the formula (li), Still yet another embodiment of the present invention provides a process for the preparation of novel intermediate of formula (li), which comprises: (i) converting the compound of formula (Id), where all symbols are as defined earlier. The compound of formula (li) may be prepared by reacting the compound of formula (Id) with a compound of formula (Ij), in the presence of a base such as triethylamine, ethyldiisopropylamine, DABCO and the like. The reaction may be carried out in the presence of a solvent such as dichloromethane, chloroform, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, acetonitrile and the like. The reaction may be carried out in the presence of Cu (1)1. It is appreciated that in any of the above-mentioned reactions, any reactive group in the substrate molecule may be protected according to conventional chemical practice. Suitable protecting groups in any of the above mentioned reactions are tertiarybutyldimethylsilyl, methoxymethyl, triphenyl methyl, benzyloxycarbonyl, tetrahydropyran(THP) etc, to protect hydroxyl or phenolic hydroxy group; N-tert-butoxycarbonyl (N-Boc), N-benzyloxycarbonyl (N-Cbz), N-9-fluorenyl methoxy carbonyl (-N-FMOC), benzophenoneimine, propargyloxy carbonyl (POC) etc, for protection of amino or anilino group, acetal protection for aldehyde, ketal protection for ketone and the like. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected. A method of treating or preventing an infectious disorder in a subject is provided by administering an effective amount of oxazolidinone as disclosed herein to the subject, wherein the infectious disorder is characterized by the presence of microbial infection caused by pathogens such as Gram-positive, Gram-negative, aerobic and anerobic bacteria such as MRSA, Pseudomonas aeruginosa, Escherischia spp., Streptococci including Str. pneumoniae, Str. pyogenes, Enterococci as well as anaerobic organisms such as Bacteroides spp., Clostridia spp. species and Acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. fastidious Gram negative organisms, H. influenzae, M. catarrhalis and several other bacteria resistant to fluoroquinolone, macrolide, Vancomycin, Aminoglycosides, Streptogramin, Lincosamides and (3-Lactam resistant species. Such disorders include infections of the middle, internal and external ear including otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, central nervous system infections, infections of teeth and gums,, infections of the mucosa, respiratory tract infections, genitourinary tract infections, gastro-intestinal infections, septicemia, bone and joint infections, skin and soft infections, bacterial endocarditis, bums, nosocomical infections, pre- and postsurgical infections, opportunistic infections in the immune compromised, intracellular infections such as Chlamydia and Mycoplasma. The pharmaceutically acceptable salts are prepared by reacting the compounds of formula (I) wherever applicable with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in the presence of a solvent like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, tromethamine, guanidine and their derivatives etc. may also be used. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in the presence of a solvent like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvent may also be used. The salts of amino acid groups and other groups may be prepared by reacting the compounds of formula (I) with the respective groups in the presence of a solvent like alcohols, ketones, ether etc. Mixture of solvents may be used. The present invention also provides pharmaceutical compositions, containing compounds of the general formula (I). The pharmaceutical compositions according to this invention can be used for the treatment of bacterial infections. They can also be used for the treatment of bacterial infections associated with multidrug resistance. The pharmaceutical compositions according to this invention can also be administered prophylatically for the prevention of bacterial infections in a patient at risk of developing a bacterial infection. Such patients include but are not limited to patients who are pre- or post-surgical, immunocompromised, or hospitalized and can be used for the treatment/prevention of bacterial infections associated with multidrug resistance. The pharmaceutical compositions may be in the forms normally employed, such as tablets, capsules, powders, dispersible granules, cachets, suppositories, syrups, solutions, suspensions and the like, may contain flavorants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 0.5 to 90 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents. Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions. The active compounds will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compounds can be combined with a suitable solid, liquid carrier or diluent to form capsules, tablets, powders, dispersible granules, cachets, suppositories, syrups, solutions, suspensions, emulsions and the like. The pharmaceutical compositions, may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like. For parenteral administration, the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds. The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans. 1/: In addition to the compounds of formula (I) the pharmaceutical compositions of the present invention may also contain or be co-administered with one or more known drugs selected from other clinically useful antibacterial agents such as P-lactams, Aminoglycosides, OxazoUdinones, Fluoroquinolines, Streptogramins, Lincosamides, Macrolides or any other suitable antiinfective agent. These may include penicillins such as oxacillin or flucloxacillin and carbapenems such as meropenem or imiphenem to broaden the therapeutic effectiveness against, for example, methicillin-resistant staphylococci. Compounds of the formula (I) of the present invention may also contain or be co-admistered with bactericidal/permeability-increasing protein product (BPI) or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents. The compounds of the formula (I) or pharmaceutical compositions thereof as defined above are clinically administered to mammals, including human beings, via oral, parenteral and/or topical routes. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absorption following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally. By either route, the dosage is in the range of about 0.1 mg/kg to about 100 mg / kg, morepreferably about 3.0 mg/kg to about 50 mg/kg of body weight of the subject per day administered singly or as a divided dose. However, the optimum dosage whether for prevention or treatment for the individual subject being treated will be determined by the person responsible for treatment. Initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administering, e.g. 2-4 times per day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. In a topical treatment an effective amount of compound of formula (I) is admixed in a pharmaceutically acceptable gel or cream vehicle that can be applied to the patient's skin at the area of treatment. Such creams and gels can be prepared by the procedures available in the literature and can include penetration enhancers. The manner in which the compounds of this invention can be prepared is illustrated in the following examples, which demonstrate the preparation of typical species of the invention. In these examples, the identities of compounds, intermediates and final, were confirmed by infrared, nuclear magnetic spectral analyses as necessary. The examples are for the purpose of illustration only and should not be regarded as limiting the invention in any way. To an ice cooled solution of propargyl amine (10 g, 182 mmol) and triefhyl amine (38 mL, 273 mmol) in tetrahydrofuran (THF) (300 mL) was added drop wise a solution of carbon disulfide (13.8 mL, 218 mmol) in THF (100 mL) through an addition funnel over a period of 0.5 h. A solution of ethylchloroformate (17.4 mL, 182 mmol) in THF (100 mL) was then added drop wise to the reaction mixture. The cooling bath was removed and the reaction mixture was allowed to stir at 20-35 °C for 15 min. The precipitate formed was then filtered off and the filtrate was concentrated at 35 °C under reduced pressure. The resulting residue was diluted with methanol (200 mL) and the solution was refluxed for 2 h. Evaporation of volatiles left a pasty mass, which was purified by passing through a silica gel column (pet. ether/ethyl acetate, 1:9) to obtain the title compound as white solid (13.6 g, 56%). A mixture of 3,4-difluomitrobenzone (24.8 g, 156 mmol) and piperizinone (13 g, 130 mmol) and triethylamine (39.4 g, 390 mmol) in dry DMF was stirred at 20-35°C overnight. Cold water was added to the reaction mixture and the solid formed was filtered. The filtered solids were dried (27.5 g, 90%). ^H NMR (DMS0-d6, 200MHz) 8 8.16 (bs, IH), 8.05-7.99 (m, 2H), 7.16 (t, J = 9.3 Hz, IH), 3.91 (s, 2H), 3.60-3.55 (m, 2H), 3.34 (s, 2H). Mass (CI method): 240, 210. IR (KBr, cm"'): 3086, 2922, 1685, 1518,1334,1232, 1072. Preparations 3-5 have been prepared according to the methodology as described in preparation 2. To a suspension of anhydrous potassium carbonate (11.80 g, 85.90 mmol) in DMF (30 ml) was added a solution of 4-piperidinone (7.20 g, 47.2 mmol) in DMF (5 ml) followed by the addition of 3,4,5-trifluoronitrobenzene (7.00 g, 42.8 mmol) and stirred at 20-35 °C for 3 h. The reaction mixture was poured onto ice water and the resulting solid was filtered off. Drying the solid under vacuum yielded the title compound as yellow powder (4.50 g, 45%). ^H NMR (CDCI3): 5 7.70 (d, J= 9.4 Hz, 2H), 3.57 (t, J = 5.9 Hz, 4H), 2.54 (t, J= 5.9 Hz, 4H); MS (m/e): 257 (M^+l)„95. Preparation 7 has been prepared according to the methodology as described in preparation 6. l-(2,6-difluoro-4-nitrophenyl)-4-piperidinone (4.50 g, 17.57 mmol), obtained in preparation 6, was added to a warm (95°C) solution of ammonium chloride (18.60 g, 351.50 mmol) in etiianol (40 ml) and water (20 ml) followed by the addition of iron powder (2.95 g, 52.7 mmol) in portion over 0.5 h and stirred at the same temperature for additional 0.5 h. The reaction mixture was extracted with ethyl acetate (2 x 250 ml). The combined extract was washed with water followed by brine and dried over sodium sulfate. Evaporation of volatiles on rota vapor yielded the title compound as viscous liquid (4.00 g, 63%). ^HNMR (CDCI3): 5 6.18 (d, J = 10.4 Hz, 2H), 3.36 (t, J- 5.7 Hz, 4H), 2.55 (t, J= 5.7 Hz, 4H); MS (m/e): 227 (M^+1), 209, 183. Preparation 9 has been prepared according to the methodology as described in preparation 8. A solution of the nitre compound (24 g, 100 mmol), obtained in preparation 3, in THF was hydrogenated over 10% Pd on charcoal (8 g) overnight. After the complete consumption of starting material, the reaction mixture was filtered over celite bed and washed with 1:1 chloroform-methanol. The filtrate was evaporated and the residue obtained was directly used for the next step (19.9 g, yield: 95 % for crude)). To a cooled (ice bath) mixture of the above obtained compound (19 g) and 50 % HCl (30 ml) (4 eq) in water was added aq. NaNO2 (12.5 g, 181 mmol) dropwise. After having stirred the reaction mixture for 5 min at the same temperature, a cold solution of sodium acetate (150 g, 108 mol) and sodium azide (11.8 g, 182 mmol) in water was added dropwise. The resultant mixture was stirred for 10 min and diluted with water. The reaction mixture was extracted with ethyl acetate and washed with water. The residue obtained upon evaporation of the solvents was used directly in the next step (12.2 g, 57%). 1H NMR (CDCl3+DMSO-d6, 200MHz): 5 7.57 (d, J = 6.8 Hz, IH), 7.00-6.75 (m, 3H), 3.70 (s, 2H), 3.44-3.28 (m, 4H). Mass (CI method): 236, 210. IR (KBr, cm"*): 3200, 3073, 2926,2116, 1685, 1510, 1309, 1231. Preparations 11 and 12 have been according to the methodology as described in preparation 10. r Sodium nitrite (2.40 g, 35.30 mmol) was added to an ice cooled solution of l-(4-amino-2,6-difluorophenyl)-4-piperidinone (4.00 g, 17.69 mmol), obtained in preparation 8, in 6 N HCl (10 mL) and the resulting solution was stirred at 0°C for 0.5 h. The reaction mixture was quenched with a saturated aqueous solution of sodium azide (2.30 g, 35.3 mmol) and sodium acetate (29.0 g, 353 mmol) over a period of 0.5 h. The reaction mixture was extracted with ethyl acetate (100 mL x 2) and the combined extract was washed with water followed by brine. The ethyl acetate extract was dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate/ pet ether; 1:9) to yield the title compound (2.20 g, 55%). ^H NMR (CDCI3): 5 6.55 (d, J= 9.4 Hz, 2H), 3.43 (t, J = 5.9 Hz, 4H), 2.57 (t, J= 5.9 Hz, 4H); MS (m/e): 253 (M^+1), 224, 212; IR (cm'^): 2116, 1720, 1629. Alternatively, the title compound can be prepared by taking Alternatively sodium azide (860 mg, 13.3 mmol), moist with water (670 ^L), was suspended in ^BuOH (4.5 mL) into which l-(4-amino-2,6-difluorophenyl)-4-piperidinone (1.0 g, 4.42 mmol) was added followed by the addition of ^BuONO (10.5 mL, 53 mmol) and the reaction mixture was stirred at rt for 6-8 h. Reaction mixture was ttien diluted with water (50 mL) and extracted with ethyl acetate (75 mL x 2). Combined ethyl acetate layer was dried over sodium sulfate and the volatiles were removed under reduced pressure. The resulting residue was purified by column chromatography (silica gel, ethyl acetate/pet. ether, 1:9) to yield the title compound (657 mg, 59%). Alternatively, the compound of preparation 14 can be prepared by taking sodium azide (860 mg, 13.3 mmol), moist with water (670 ^iL), was suspended in ^BuOH (4.5 mL) into which l-(4-amino-2-fluorophenyl)-4-piperidinone (920 mg, 4.42 mmol) was added followed by the addition of/-BuONO (10.5 mL, 53 mmol) and the reaction mixture was stirred at rt for 6-8 h. Reaction mixture was then diluted with water (50 mL) and extracted with ethyl acetate (75 mL x 2). Combined ethyl acetate layer was dried over sodium sulfate and the volatiles were removed under reduced pressure. The resulting residue was purified by column chromatography (silica gel, ethyl acetate/pet. ether, 1:9) to yield the title compound (672 mg, 65%). To a solution of the appropriate azide (3 g, 12.7 mmol), obtained in preparation 2, in dichloromethane (CH2Cl2)(100 mL) at 20-35 °C under argon was added (BOC)2O (4.17 g, 19.1 mmol), dimethylaminopyridine (DMAP) (0.155 g, 1.3 mmol) and EtaN (2.57 g, 2515 mmol). The reaction mixture was stirred for 12 h at the same temperature and the reaction mixture was concentrated. The residue obtained was chromatographed over silica gel to afford the title compound (4.14 g, 97%). 1H NMR (CDCI3, 200MHz) 6 6.88-6.74 (m, 3H), 3.86-3.80 (m, 4H), 3.37 (t, 7 = 5.4 Hz, 2H), 1.55 (s, 9H). Mass (CI method): 336, 307, 280. IR (KBr, cm"'): 3436, 2989, 2925, 2863,2115, 1727,1706,1510, 1309. * BOC: tert-butoxycarbonyl Preparations 16 and 17 have been prepared according to the methodology as described in preparation 15. F To a solution of l-(4-azido-2,6-difluorophenyl)-4-piperidinone (500 mg, 1,98 mmol), obtained in preparation 13, and hydroxylamine hydrochloride (275 mg, 3.96 mmol) in methanol (5 mL) was added pyridine (313 mg, 3.96 mmol) and refluxed for 1 h. The reaction mixture was diluted with ethyl acetate (200 mL) and the organic phase was washed with water followed by brine and dried over sodium sulfate. Evaporation of volatiles afforded the title compound as white solid (400 mg, 75%). To a solution of l-(4-azido-2,6-difluoro-phenyl)-4"piperidin-4-one oxime (400 mg, 1.58 mmol), obtained in preparation 18, and sodium hydroxide (126 mg, 3.16 mmol) in a mixture of dioxane/water (3:4, 5 mL) at 0 °C was added p-toluene sulfonyl chloride (450 mg, 2.37 mmol) and stirred at 20-35°C for 24 h. The reaction mixture was diluted with ethyl acetate (200 mL) and the organic phase was washed with water followed by brine and dried over sodium sulfate. Evaporation of volatiles afforded the title compound as white solid (150 mg, 40%). To a solution of l-(4-azido-2,6-difluoro-phenyl)-[l,4]diazepan-5-one (300 mg, 1.12 mmol), obtained in preparation 20, in DMF (2 mL) was added 60% NaH (80 mg, 3.37 mmol) at 0 °C and stirred for 0.5 h . Methyl iodide (316 mg, 2.24 mmol) was added to the above mixture at the same temperature and stirred at 20-35°C for 2 h. The reaction mixture was quenched with brine and extracted with ethyl acetate (100 mL x 2), The combined organic layer was dried over sodium sulfate. The residue obtained after removal of volatiles was purified by column chromatography over silica gel (ethyl acetate/ pet ether; 4:5) to obtain the title compound (200 mg, 63%). 'H NMR (CDC13): 5 6.56 (d, J= 8.7 Hz, 2H), 3.57-3.53 (m, 2H), 3.30-3.15 (m, 4H), 3.04 (s, 3H), 2.82-2.70 (m, 2H); MS (m/e): 282 (M++1), 270, 253, 234, 193; IR (cm"'): 2112, 1651,1573,1501. 1.123 mmol), obtained in preparation 20, in DMF (2 mL) was added NaH (60%, 80 mg, 3.40 mmol) at 0 oC and stirred for 0.5 h . Ethyl iodide (350 mg, 2.24 mmol) was added to the above mixture at the same temperature and stirred at 20-3 5 oC for 2 h. The reaction mixture was quenched with brine and extracted with ethyl acetate (100 mL x 2). The combined organic layer was dried over sodium sulfate. The solvent was evaporated and the resulting residue was purified by column chromatography over silica gel (ethyl acetate/ pet ether; 1:1) to obtain the title compound (200 mg, 59%). 1H NMR (CDC13): 5 6.55 (d, J= 9.2 Hz, 2H), 3.55-3.42 (m, 4H), 3.24-3.19 (m, 4H), 2.80-2.75 (m, 2H), 1.14 (t, /= 7.0 Hz, 3H); MS (m/e): 296 (M^+1), 270, 267; IR (cm'*): 2927, 2116,1650, 1572,1503. Preparation 25 has been prepared according to the methodology as described in preparation 24. To a solution of l-(4-azido-2-fluoro-phenyl)-[l,4]diazepan-5-one (300 mg, 1.2 mmol), obtained in preparation 20, and formaldehyde (10 mL) was refluxed under nitrogen for 16 h. The reaction mixture was diluted with ethyl acetate (100 mL), washed successively with water (20 mL) and brine (20 mL). The solvent was dried over sodium sulfate and evaporated on a rotavapor. The crude material was purified by silica gel column chromatography (ethyl acetate/pet ether; 1:1) to obtain the title compound (100 mg, 30%). A mixture of the azide (2.7 g, 8.1 mmol), obtained in preparation 15, Cul (2.3 g, 12.1 mmol) and propargyl alcohol (1.67 g, 12.1 mmol) in 1:1 mixture of diisopropyl ethylamine and acetonitrile (20 mL) was stirred at 20-35 °C for 12 h. Saturated NH4CI solution (10 mL) was added to the reaction mixture. Stirred for 15 min, 2 mL of aqueous ammonia solution was added and stirred for 5 min. The resultant mixture was extracted with ethylacetate. The organic layer was washed with brine The reaction mixture was concentrated afford the product (3 g, 97% for crude). 1H NMR (CDCl3+DMSO-d6, 200MHz) 5 8.13 (s, IH), 7.63-7.49 (m, 2H), 7.06 (t, 7 = 8.7 Hz, IH), 4.79 (d, J= 5.6 Hz, 2H), 3.97-3.86 (m, 4H), 3.53-3.48 (m, 2H), 1.56 (s, 9H). Mass (CI method): 392, 292. . IR (KBr, cm-1): 3499, 1760, 1531, 1148. Preparations 30: 4_[4-(4-Azidomethyl-4H-[l,2,3]triazo-l-1-yl)-2-fluoro-phenyl]-piperazin-2-oneacetic acid tert-butyl ester; To a solution of the alcohol (2.5 g, 6.4 mmol), obtained in preparation 27, triethylamine (0.97 g, 9.5 nunol),in dry dichloromethane (100 mL) was added methane sulfonylchloride (0.878 g, 7.6 mmol) at 0 °C. The reaction mixture was warmed to 20-35 °C over 1 h and then diluted with dichloromethane. The organic layer was washed with water, brine and dried. The residue obtained upon evaporation of the solvent was taken up in dry DMF and then NaNs (0.748 g, 11.51 mmol) was added at 20-35 °C. The resultant mixture was heated to 80 °C for 2 h while monitoring by TLC. After having allowed the reaction mixture to attain 20-35 °C, water was added and extracted with ethyl acetate. The combined organic extracts were washed with water (3 times), brine and dried. The residue obtained upon evaporation of the solvent was passed through column to obtain the title compound (2.2 g, 82.7 %). 1H NMR (DMSO-d6, 200MHz) 5 8.83 (s, IH), 7.83 (dd, 7= 11.7 Hz & 1.9 Hz, IH), 7.70 (d, y = 8.8 Hz, IH), 7.22 (t, / = 9.3 Hz, IH), 4.60 (s, 2H), 4.00 (s, 2H), 3.80-3.70 (m, 2H), 1.47 (s, IH). Mass (CI method): 417, 317, 289. IR (KBr, cm'*): 3128, 2926, 2101, 1760, 1521,1309,1249,1147. Preparations 31 and 32 have been prepared according to the methodology as described in preparation 30. A solution of azide compound (2.2 g, 5.3 mmol), obtained in preparation 30, and trifluoroacetic acid (TFA) (4 mL) in CH2CI2 (100 mL) was stirred for 12 h. The volatiles were removed and the residue obtained was passed through column to obtain the product (1.5 g, 95%).. 'H NMR (CDCl3+DMSO-d6, 200MHz): 5 8.20 (s, IH), 7.64-7.50 (m, 3H), 7.07 (t, 7= 8.8 Hz, IH), 4.56 (s, 2H), 3.82 (s, 2H), 3.48-3.45 (m, 4H). Mass (CI method): 317, 246, 190.. IR (KBr, cm-^): 2927, 2101, 1682, 1520, 1241, 1049. Examples 2 and 3 have been prepared according o the methodology as described in example 1. Triphenyl phosphine (1.49 g, 5.7 mmol) was added portion wise to a solution of the azide compound (1.5 g, 4.74 mmol), obtained in example 1, in THF and the resultant mixture was stirred at room temperature for 5 h. Water (1 mL) was added and the reaction mixture was heated to 60 °C for 12 h. The solvent was evaporated and the residue was passed through a column of silica gel to afford the amine (1.2 g, 93%). Examples 5-7 have been prepared according o the methodology as described in example 4. Example 8: N-{l-[3,5-Difluoro-4-(3-oxo-piperazin-l-yl)-phenyl]-4H-[l,2,3]triazol-4-ylmethyl}-acetamide To a solution of the amine (100 mg, 0.3 mmol), obtained in example 7, in CH2CI2 at 0 °C under argon was added EtaN (93 mg, 0.9 mmol) followed by acetylchloride (36 mg, 0.46 mmol) drop wise. After being stirred at 20-35 °C for 4 h, the reaction mixture was diluted with dichloromethane and washed with water twice followed by brine. The dried organic extract was evaporated of the residue obtained was passed through column to afford the acylated product (80 mg, 75%). 1H NMR (200 MHz, DMSO-de) 8: 8.67 (s, IH), 8.45 (bs, IH), 7.99 (s, IH), 7.76 (d, 7 = 9.8 Hz, 2H), 4.36 (d, 7= 5.4 Hz, 2H), 3.72 (s, 2H), 3.38-3.28 (m, 4H), 1.87 (s, 3H). Examples 9-11 have been prepared according 0 the methodology as described in example 8. To a solution of the amine (80 mg, 0.28 mmol), obtained in example 4, and Et3N (84 mg, 0.83 mmol) in THF was added ethyldithioacetate (40 mg, 0.33 mmmol) at 20-35 oC and then the reaction mixture was stirred overnight. The volatiles were removed and the residue obtained was passed through column of silica gel to afford the thioacetate (60 mg, 63%). 1H NMR (200 MHz, DMSO-d6) 8: 10.48 (bs, IH), 8.72 (s, IH), 8.05 (s, IH), 7.85-7.68 (m, 2H), 7.23 (t, J= 9.0 Hz, IH), 4.82 (d, J= 4.4 Hz, 2H), 3.69 (s, 2H), 3.38-3.28 (m, 4H), 2.50-2.44 (m, 3H). Examples 14-16 have been prepared according o the methodology as described in example 13, Example 17: {l-[3-Fluoro-4-(3-oxO"piperazin-l-yl)-phenyl]-4H-[l,2,3]triazol-4-ylmethyl}-carbamic acid methyl ester To a solution of the amine (80 mg, 0.28 mmol), obtained in example 4, Et3N (84 mg, 0.83 mmol) in dry dichloromethane at 0°C under argon was added methyl chloroformate (39 mg, 0.41 mmol). The reaction mixture was stirred at 20-35 C overnight and worked up by diluting with dichloromethane followed by washing with water and brine. The residue obtained after evaporation of the dried organic layer was passed through column to afford the carbamate (60 mg, 63%). 1H NMR (200 MHz, DMSO-d6) 8: 8.60 (s, IH), 8.15-7.60 (m, 3H), 7.22 (t, 7= 9.3 Hz, IH), 4.31 (d, J= 5.9 Hz, 2H), 3.69 (s, 2H), 3.56 (s, 3H), 3.34-2.73 (m, 4H). Step (i): Thiophosgene (1.2 eq) was added drop wise to a solution of the amine (1 eq), obtained in examples 5-8, Et3N (2.4 eq) in dry dichloromethane at ice bath temperature under argon. The reaction mixture was wanned to room temperature over 3 h and then the volatiles were removed. The residue obtained was directly charged on to a column of silica gel to afford the product. Step (ii): A solution of the isothiocyanate (100 mg, 0.29 mmol) was refluxed while monitoring by TLC. At the complete consumption of starting material, the reaction mixture was allowed to cool to 20-35 °C. The crystals formed were separated, washed with ether and dried at vacuum to yield the pure product (70 mg, 62 %). 1H NMR (200 MHz, DMSO-d6) 5: 9.61-9.59 (m, IH), 8.63 (d, 7 = 9.8 Hz, IH), 8.04 (s, IH), 7.90-7.60 (m, 2H), 7.22 (t,J= 9.3 Hz, IH), 4.72 (d, 7- 5.4 Hz, 2H), 4.45-4.35 (m, 2H), 3.69 (s, 2H), 3.34-2.73 (m, 4H), 1.25 (t, 7 = 6.8 Hz, 3H). Examples 20-32 have been prepared according o the methodology as described in example 19. To a DMF solution (2 ml) of l-(4-azido-2,6-difluoro-phenyl)-[l,4]diazepan-5-one (140 mg, 0.52 mmol), obtained in preparation 20, and diisopropylethyl amine (75 mg, 0.58 mmol) was added prop-2-ynyl-thiocarbamic acid 0-methyl ester (100 mg, 0.78 mmol) followed by the addition of cuprous iodide (199 mg, 1.05 mmol) in portion and stirred at 20-35 °C for 0.5 h. Saturated solution of ammonium chloride (5 ml) was added to the reaction mixture followed by the addition of two drops of ammonium hydroxide solution. The reaction mixture was then extracted with ethyl acetate (100 ml x 2) and the organic phase was washed with water followed by brine and dried over sodium sulfate. Evaporation of volatiles on rotavapor and purification of the resulting residue through silica gel column (methanol/chloroform, 1:5) yielded the title compound (80 mg, 40%). Mp 185-187 °C 'H NMR (CDCI3): 5 8.17 (s, IH), 8.02-7.93 (m, 2H), 7.90-7.62 (m, 4H), 7.55 (t, 7= 7.5 Hz, IH), 6.92 (bs, IH), 4.93 & 4.72 (2 d, J= 5.9 Hz, 2H, rotamers in a ratio of 4:1), 4.13 & 4.01 (2 s, 3H, rotamers in a ratio of 1:4); MS (m/e): 412 (M^+1), 380, 323, 257; IR (KBr,cm-'): 1731,1528,1384. Examples 35-39 have been prepared according to the methodology as described in example 34. A solution of isothiocyanate (100 mg, 0.3 mmol), obtained in step (i) of example 19, and aqueous ammonia (5 mL) was stirred at 20-35 °C for 2 h. The residue obtained upon evaporation of the volatiles was passed through a column of silica gel to afford the product (60 mg, 57%, yield). 1H NMR (400 MHz, DMSO-d6) 5: 8.64 (s, IH), 8.12 (bs, IH), 8.01 (s, IH), 7.80 (dd, 7 = 11.2 Hz & 2.4 Hz, IH), 7.68 (dd, 7= 6.3 Hz & 2.2 Hz, IH), 7.22 (t, J= 9.3 Hz, IH), 4.70 (bs, 2H), 3.69 (s, 2H), 3.34-3.26 (m, 4H). MP: 198-200°C Example 47: Morpholine-4-carbothioic acid {l-[3-fluoro-4-(3-oxo-piperazin-l-yl)-phenyl]-4H- [l,2,3]triazol-4-ylmethyl}-amide A solution of the isothiocyanate (100 mg, 0.3 mmol), obtained in step (i) of example 4 and morpholine (22 mg, 0.3 mmol) in THF was stirred at 20-35 °C over 30 min. The volatiles were removed and the residue obtained was passed through column of siUca gel to afford the product (72 mg, 57%). 1H NMR (400 MHz, DMSO-d6) 5: 8.60 (s, IH), 8.23 (t, J = 5.1 Hz, IH), 8.01 (s, IH), 7.81 (dd, J= 11.2 Hz & 2.4 Hz, IH), 7.68 (dt, J = 5.9 Hz & 1.3 Hz, IH), 7.22 (t, 7 = 9.3 Hz, IH), 4.87 (d, y = 4.9 Hz, 2H), 3.79-3.77 (m, 4H), 3.69 (s, 2H), 3.61-3.59 (m, 4H), 3.35- 3.25 (m, 4H). Example 48 has been prepared according o the methodology as described in example 47. In vitro Data Minimum Inhibiton Concentrations (MICs) were determined by broth microdilution technique as per the guidelines prescribed in the fifth edition of Approved Standards, NCCLS document M7-A5 Vol 20 - No 2, 2000 Villinova, PA. Initial stock solution of the test compound was prepared in DMSO. Subsequent two fold dilutions were carried out in sterile Mueller Hinton Broth (Difco) (MHB). Frozen cultures stocks were inoculated into 50 ml sterile MHB in 250 ml Erlyn Meyer flasks. Composition of MHB is as follows: Beef Extract Powder - 2.0 g/litre Acid Digest of Casein - 17.5 g/ litre Soluble Starch - 1.5 g/litre Final pH 7.3 ±0.1 Flasks were incubated for 4 to 5 h at 35 *"€ on a rotary shaker at 150 rpm. Inoculum was prepared by diluting the culture in sterile MHB to obtain a turbidity of 0.5 McFarland standard. This corresponds to 1-2 x 10^ CFU/ml. The stock was further diluted in sterile broth to obtain 1-2 X 10 CFU/ml. 50 µl of the above diluted inoculum was added from 1-10 wells. The plates were incubated overnight at 37 °C. MIC is read as the lowest concentration of the compound that completely inhibits growth of the organism in the microdilution wells as detected by the unaided eye. NCTC: National Collections of Type Cultures, Colindale, UK DRCC: Dr. Reddy's Culture Collection, Hyderabad, India. The in vitro antibacterial activity data is shown in TABLE 1. TABLE 1 In vivo efficacy studies: Mice Systemic Infection • S.aureus ATCC 29213 and other tested strains were grown overnight on Columbia Blood agar (DIFCO). • The inoculum was prepared by suspending the culture in 0.9% saline and adjusted to 100 X LD50 dose in 10% Hog Gastric Mucin (DIFCO). 0.5ml was injected intraperitonially to Swiss albino mice weighing 18-22g (n=6) • Test compounds were solubilised in suitable formulation and 0.25ml was administered intra venously or orally or sub-cutaneously at 1 hr and 5 hr post infection by BID or TID or single dose protocol • The animals were observed for 5-7 days and the survival was noted. • ED50 was calculated by probit analysis. We claim: 1. Novel triazole compounds of the general formula (I), and their pharmaceutically acceptable salts thereof, where R1 represents halogen, azido, thioalcohol, isothiocyanate, hydroxy, isoindole-1,3-dione, optionally substituted (C1-C10)alkylsulfonyloxy, arylsulfonyloxy, (C1-10)acyloxy group, -SO2-(C1-C10)alkyl, -SO2-aryl, where Q represents oxygen or sulfur, R5 represents (i) hydrogen. Optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (ix) aryloxy, (xii) heteroaryl, (xiii) heterocyclyl, (xii) heteroaryloxy, (xiii) -NH-R6, where R6 epresents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, and Q1 represents oxygen or sulfur; (xiv) -N-[alkyl]2, (xv) -N(R'R"), wherein R' and R" together form a optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; (xvi) -SR , wherein R is as defined above; where R represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, aryl or aralkyl; R6 represents optionally substituted groups selected from (i) alkyl, (ii) cycloalkyl, (iii) alkoxy, (iv) cycloalkoxy, (v) alkenyl, (vi) alkenyloxy, (vii) aryl, (viii) aryloxy, (ix) heteroaryl, (x) heteroaryloxy, (xi) -NH-R10, where R10 represents hydrogen or optionally substituted -alkyl, (xii) -N-[alkyl]2; R1, and R3 at each occurrence are the same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) OR^ where R^ represents hydrogen or optionally substituted alkyl group; Y*1represents =O, Y1, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR ) where R represents alkyl, haloalkyl, hydroxyalkyl, aiyl or aralkyl group; (ii) -NR*' where R^ represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyi, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3; and n represents 1-3. 2. The compound of the formula (I) as defined according to claim 1 which is selected from: where Q represents oxygen or sulfur, R5 represents (i) hydrogen, optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (ix) aryloxy, (x) heteroaryl, (xi) heterocyclyl, (xii) heteroaryloxy, (xiii) -NH-R6, where R6 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, R2, and R3 at each occurrence are the same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORq where Ra represents hydrogen or optionally substituted alkyl group; Y , and Y may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl. 4. Novel triazole compounds that have the general formula (lib) and their pharmaceutically acceptable salts thereof, where R^ represents (i) hydrogen, optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (ix) heteroaryl, and optionally having one or two additional hetero atoms selected from O, S or N. 7. The compound of claim 4 having the structure Optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (ix) heteroaryl, (x) heterocyclyl, (xi) -NH-R6, where R6 represents hydrogen, optionally substituted groups selected from alkyl or cycloalkyl (xii) -N-[alkyl]2, (xiii) -N(R'R"), wherein R' and R" together form a optionally substituted substituted a 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; Y2, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent hydrogen, cyano, amino, formyl, =0, =S, alkyl or hydroxyalkyl; R2, and R3 at each occurrence are the same or different and are selected from hydrogen, halogen, cyano, hydroxyl, alkyl, haloalkyl; m represents 0-3, n represents 1-3. 13. The compound of claim 12, wherein R5 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, alkenyloxy, -NH-R^ where in R6 represents hydrogen, alkyl or cycloalkyl, -N-[alkyl]2, -N(R'R") wherein R' and R" together form a optionally substituted a 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N. 14. The compound of claim 12 having the structure R , and R at each occurrence are the same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y1 represents =O, Y2, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR ) where R represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3; and n represents 1-3; which comprises: (i) reacting the compound of formula (la) where X represents halogen atom, R and R are as defined above, with a compound of formula (lb) where R1 represents azido group and all other symbols are as defined above and (vi) converting the compound of formula (If) to a compound of formula (I), where R1 represents azido group followed by compound of formula (I) where R1 represents amino group and all other symbols are as defined above. 26. A process for the preparation of the compound of formula (I) and in all the above processes, R2, and R3 at each occurrence are the same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y1 represents =O, Y2 and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =0, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR12) where R12 represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -Nb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3 and n represents 1-3; which comprises: using compound of formula (I), where R* represents NHR'* wherein R** represents hydrogen atom and all other symbols are as defined above, under various reaction conditions. 27. A process for the preparation of compound of formula (I) where Q represents oxygen or sulfur, R^ represents (i) hydrogen. Optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (ix) aryloxy, (x) heteroaryl, (xi) heterocyclyl, (xii) heteroaryloxy, (xiii) -NH-R6, where R6 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, aryl or aralkyl; R^ represents optionally substituted groups selected from (i) alkyl, (ii) cycloalkyl, (iii) alkoxy, (iv) cycloalkoxy, (v) alkenyl, (vi) alkenyloxy, (vii) aryl, (viii) aryloxy, (ix) heteroaryl, (x) heteroaryloxy, (xi) -NH-R10, where R10 represents hydrogen or optionally substituted -alkyl. (xii) -N-[alkyl]2; R , and R at each occurrence are the same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y1 represents =O, Y , and Y may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (x) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR^^) where R'^ represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; which comprises: (i) reacting the compound of formula (la) where all symbols are as defined above, (iii) converting the compound of formula (Id) to a compound of formula (le), (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y1 represents =O, Y2, and Y2 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =0, (ix) =S, Optionally substituted groups selected from (x) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino. (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR12) where R12 represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3 and n represents 1-3; optionally substituted 5 or 6 membered cyclic structures containing nitrogen and optionally one or two additional hetero atoms selected from oxygen, nitrogen or sulfur; R2, and R3 at each occurrence are same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y1 represents =O, Y2, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR12) where R12 represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3 and n represents 1-3; which comprises: converting a compound of formula (I), where R1 represents isothiocyanate group. 30. A process for the preparation of compound of formula (I) where R1 represents NHR4 where R4 represents optionally substituted group selected from -C(=NH)-NH2; R , and R at each occurrence are same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) OR1 where R1 represents hydrogen or optionally substituted alkyl group; Y1 represents =O, Y1, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro. (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR ) where R represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3 and n represents 1-3; which comprises: converting the compound of formula (I), where R1 represents NHR wherein R4 represents optionally substituted group selected from -S(O)2(C1-C10)alkyl or -S(0)2aryl group 31. A process for the preparation of compound of formula (I) where R^ represents halogen, azido, thioalcohol, isothiocyanate, hydroxy, isoindole-1,3-dione, optionally substituted (C1-C10)alkylsulfonyloxy, arylsulfonyloxy, (C1-C10)acyloxy group, -SO2-(C1-C10)alkyl, -SOz-aryl; NHR4 where R4 represents hydrogen, where Q represents oxygen or sulfur, R5 represents (i) hydrogen. Optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl, (ix) aryloxy, (x) heteroaryl, (xi) heterocyclyl, (xii) heteroaryloxy, (xiii) -NH-R6, where R6 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, (xv) -N(R'R"), wherein R' and R" together form a optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; (xvi) -SR , wherein R is as defined above; R6 represents optionally substituted groups selected from (i) alkyl, (ii) cycloalkyl, (iii) alkoxy, (iv) cycloalkoxy, (v) alkenyl, (vi) alkenyloxy, (vii) aryl, (viii) aryloxy, (ix) heteroaryl, (x) heteroaryloxy, (xi) -NH-R^*^, where R^^represents hydrogen or optionally substituted -alkyl, (xii) -N-[alkyl]2; R2, and R6 at each occurrence are the same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, independently represent hydrogen atom, Z represents -NRb where Rb represents hydrogen atom; m represents 0-3; and n represents 1-3. where Q represents oxygen or sulfur, R5 represents (i) hydrogen, Optionally substituted groups selected from (ii) alkyl, (iii) cycloalkyl, (iv) alkoxy, (v) cycloalkoxy, (vi) alkenyl, (vii) alkenyloxy, (viii) aryl. (ix) aryloxy, (x) heteroaryl, (xi) heterocyclyl, (xii) heteroaryloxy, (xiii) -NH-R^, where R^ represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, (i) alkyl, (ii) cycloalkyl, (iii) alkoxy, (iv) cycloalkoxy, (v) alkenyl, (vi) alkenyloxy, (vii) aryl, (viii) aryloxy, (ix) heteroaryl, (x) heteroaryloxy, (xi) -NH-R10, where R10 represents hydrogen or optionally substituted -alkyl, (xii) -N-[alkyl]2; R2, and R3 at each occurrence are the same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y2, represents =O, Y2, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent hydrogen atom, Z represents NR wherein R represents optionally substituted (C1-C6)alkyl or aralkyl; m represents 0-3; and n represents 1-3. which comprises: converting a compound of formula (I), where where Z represents NRb wherein Rb represents hydrogen, Y1 represents '=O' group, Y2 and Y3 independently represent hydrogen atom and all other symbols are as defined above. 33, A process for the preparation of compound of formula (I) hydroxy(Ci-C6)alkyl and R" represents hydrogen or alkyl or the two R' and R" groups together form a 5 or 6 membered cyclic structures containing one or two hetero atoms selected from oxygen, sulfur or nitrogen; R2 , and R3 at each occurrence are same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORa where Rb represents hydrogen or optionally substituted alkyl group; Y' represents =O, Y , and Y may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (x) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR12) where R12 represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NRb where Rbrepresents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3 and n represents 1-3; which comprises: converting a compound of formula (I), where R* represents isothiocynate group and all other symbols are as defined above. 34. A compound of formula (Ii) (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) OR1 where Ra represents hydrogen or optionally substituted alkyl group; Y' represents =O, Y2, and Y2 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano. (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR12) where R12 represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NR where R represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino; m represents 0-3 and n represents 1-3. 35. A novel compound of formula (If) R^, and R^ at each occurrence are same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl, (viii) ORa where R1 represents hydrogen or optionally substituted alkyl group; Y1 represents =O, Y2, and Y3 may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (x) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl. (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (ii) -NRb where Rb represents hydrogen; m represents 0-3 and n represents 1-3. R , and R at each occurrence are same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alky], (vii) haloalkyl, (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y' represents =0, Y^, and Y^ may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents NR where R*^ represents hydrogen; m represents 0-3 and n represents 1-3. 37. A pharmaceutical composition comprising a) an antibacterially effective amount of the compound of claim 1, 2, 3, 4 or 12; and b) a pharmaceutically acceptable carrier, diluent, excipient or solvate. 38. The pharmaceutical composition of claim 37, which is a tablet, a capsule, a powder, a syrup, a solution or a suspension. 39. A method for inhibiting the growth of bacteria in humans and non-human mammals suffering bacterial infections, which comprises administering to a subject suffering such infection an antibacterially effective dose of the compound of claim 1, 2, 3, 4 or 12. 40. The method according to claim 1, 2, 3, 4 or 12, wherein the bacterial infection is caused by the drug susceptible or resistance pathogens. 41. The method according to claim 40, wherein drug resistance pathogens are selected from Methicillin-Resistant Staphylococcus Aureas (MRSA), streptococci, enterococci, anaerobic organisms, Clostridia spp. species and acid-fast organisms. 42. The method of claim 40, wherein said drug resistance pathogens are Str pneumoniae or Str pyogenes. 43. The method of claim 40, wherein said drug resistance pathogen is Bacteroides spp. 44. The method of claim 40, wherein said drug resistance pathogen is Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. Fastidious Gram negative organisms, Hemophilus influenzae (H Influenzae) or Morexella catarrhalis (M Catarrhalis). 45. The method of claim 39, wherein the bacterial infection is caused by the Fluoroquinolone resitant bacteria, Macrolide resistant bacteria. Vancomycin resitatn bacteria and P-lactam resistant bacteria. 46. The method of claim 39, further comprising administering a second antibacterial agent in combination with the compound of claim 1,2, 3,4 or 12, to said subject. 47. The method of claim 46, wherein said second antibacterial agent is selected from the group consisting of P-lactams, aminoglycosides, other oxazolidinones, fluoroquinolines, and macrolides. 48. A compound of formula (I) where R' represents NHR4 where R4 represents acetyl group; R2, and R3 at each occurrence are same or different and are (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) amino Optionally substituted groups selected from (vi) alkyl, (vii) haloalkyl. (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; Y1 represents =O, Y , and Y may be present on any of the carbon atoms of the hetercyclic ring and are independently represent (i) hydrogen, (ii) halogen, (iii) cyano, (iv) nitro, (v) formyl, (vi) hydroxy, (vii) amino, (viii) =O, (ix) =S, Optionally substituted groups selected from (X) alkyl, (xi) hydroxyalkyl, (xii) alkoxyalkyl, (xiii) alkoxycarbonyl, (xiv) carboxyalkyl, (xv) alkylsulfonyl, (xvi) aminoalkyl, (xvii) monoalkylamino, (xviii) dialkylamino, (xix) arylamino, (xx) alkoxy, (xxi) aryl, (xxii) aryloxy, (xxiii) aralkyl or (xxiv) heteroaryl, Z represents (i) -C(=NOR12) where R12 represents alkyl, haloalkyl, hydroxyalkyl, aryl or aralkyl group; (ii) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyi, monoalkylamino, dialkylamino, arylamino; m represents 0-3 and n represents 1-3; which comprises: reacting the compound of formula (I) where R1 represents azido group and all other symbols are as defined above.

Documents:

0824-che-2003 abstract-duplicate.jpg

0824-che-2003 abstract-duplicate.pdf

0824-che-2003 claims-duplicate.pdf

0824-che-2003 description (complete)-duplicate.pdf

824-che-2003-abstract.pdf

824-che-2003-claims.pdf

824-che-2003-correspondence others.pdf

824-che-2003-correspondence po.pdf

824-che-2003-description complete.pdf

824-che-2003-form 1.pdf

824-che-2003-form 18.pdf

824-che-2003-form 3.pdf

824-che-2003-pct.pdf

abs-824-che-2003.jpg